Catalent’s recent deal to help produce 100 million doses of Moderna’s COVID-19 vaccine candidate is expected to result in 300 new jobs at the Bloomington facility. This is in addition to the 300 new jobs coming from a similar deal with Johnson & Johnson announced in April.

Hundreds of new job openings have already posted and more will go up soon on the Catalent website, said Denis Johnson, general manager of the Bloomington facility.

“We’re in the process of ramping up hiring, especially for skill positions that require more training,” he said.

The deal with Moderna, a biotechnology company headquartered in Cambridge, Massachusetts, was announced publicly Thursday. According to a news release from Catalent, the Bloomington facility will fill vials and package 100 million doses of Moderna’s COVID-19 vaccine candidate. The companies are in discussions for continued production of hundreds of millions of additional doses, according to the release.

Moderna and Johnson & Johnson were among five companies the Trump Administration selected as the most likely candidates to produce a vaccine for the novel coronavirus. This designation provides access to federal funding to speed testing and create a manufacturing base before it’s clear that any of the vaccines in development will work.

© 2020 HeraldTimesOnline, Bloomington, IN